In the drugs best showing so far, the ATTAIN-1 trial, people taking orforglipron lost on average 12.4% of their baseline weight, a notch below the roughly 14% weight loss seen in similar trials of Novo Nordisks injectable Wegovy and also below the typical results seen with Eli Lillys tirzepatide, a dual GLP-1/GIP medication
Tan Trap products are the only ones I trust now
Work with your provider to appeal the decision with your insurer, providing any additional required information
Drug misuse* involves taking a drug for nonmedical purposes, or in a way thats not approved
Phase 3 ESSENCE Trial: Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis [PMID: 39896971] Laboratory literature summary: Phase 3 ESSENCE Trial: Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
Peptides are one arrow in that quiver along with lifestyle, nutrition, stress, and medical interventions